SCHEMBL3673064

SCHEMBL3673064

Cc1c(CCC(=O)O)ccc(C(C)(C)C)c1O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.44
POLB P06746 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
FFAR4 Q5NUL3 5/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
CA2 P00918 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GLRA3 O75311 1/20 0.36
GLRB P48167 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ESR1 P03372 1/20 0.36
CYP3A4 P08684 1/20 0.36
ESR2 Q92731 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163934 0.84 POLB (0.42) NPSR1POLBNR1H4FFAR4RXRA
SCHEMBL11581053 0.81 NPSR1 (0.49) NPSR1POLBNR1H4RXRARXRB
SCHEMBL8520513 0.81 POLB (0.42) NPSR1POLBNR1H4FFAR4RXRA
SCHEMBL23940954 0.79 CA2 (0.45) NPSR1POLBCA2GABRA1GABRB2
SCHEMBL30501159 0.79 CA2 (0.52) NPSR1POLBNR1H4CA2GABRA1
SCHEMBL4975584 0.79 CA2 (0.52) NPSR1POLBNR1H4CA2GABRA1
SCHEMBL740968 0.79 POLB (0.50) NPSR1POLBNR1H4RXRARXRB
SCHEMBL16196207 0.78 NPSR1 (0.46) NPSR1POLBNR1H4RXRARXRB
SCHEMBL7693390 0.77 NR1H4 (0.48) NPSR1POLBNR1H4FFAR4RXRA
Methane SCHEMBL8628685 0.77 POLB (0.49) NPSR1POLBNR1H4RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4333852-A1 LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF Enalare Therapeutics Inc. (US) 2024-03-13 EP disclosed
EP-4333807-A1 NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF Sovida Solutions Ltd. (GB) 2024-03-13 EP disclosed
EP-4312941-A1 PHOSPHOLIPIDS AS ANION CHELATING AGENTS IN PHARMACEUTICAL FORMULATIONS R.P. Scherer Technologies, LLC (US) 2024-02-07 EP disclosed
EP-4121164-A1 MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT Tauriga Sciences Inc. (US) 2023-01-25 EP disclosed
WO-2022197581-A1 NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT TAURIGA SCIENCES INC. (US) 2022-09-22 WO disclosed
WO-2021188612-A1 MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT TAURIGA SCIENCES INC. (US) 2021-09-23 WO disclosed
EP-3850040-A1 A STABILIZED CHLORINATED POLYVINYLCHLORIDE AND AN ARTICLE MADE THEREFROM Reagens S.p.A. (IT) 2021-07-21 EP disclosed
WO-2021087210-A1 SUPPOSITORY CAPSULE R.P. SCHERER TECHNOLOGIES, LLC (US) 2021-05-06 WO disclosed
EP-3649189-A1 A POLYETHYLENE PIPE BASF SE (DE) 2020-05-13 EP disclosed
WO-2020053157-A1 A STABILIZED CHLORINATED POLYVINYLCHLORIDE AND AN ARTICLE MADE THEREFROM REAGENS S.P.A. (IT) 2020-03-19 WO disclosed
WO-2012004377-A1 STABILIZING COMPOSITION FOR HALOGEN-CONTAINING POLYMERS REAGENS S.P.A. (IT) 2012-01-12 WO disclosed
WO-2012000992-A1 PROCESS FOR IMPROVING THE FLOW PROPERTIES OF POLYMER MELTS BASF SE (DE) 2012-01-05 WO disclosed
EP-2150576-A1 STABILIZATION OF POLYMERS WITH STYRENATED-P-CRESOLS CHEMTURA CORPORATION (US) 2010-02-10 EP disclosed
WO-2008144086-A1 STABILIZATION OF POLYMERS WITH STYRENATED-P-CRESOLS CHEMTURA CORPORATION (US) 2008-11-27 WO disclosed
US-6770693-B2 COMPRISING BIS-(2,4-DICUMYLPHENYL) PENTAERYTHRITOL DIPHOSPHITE AND HINDERED PHENOL ANTIOXIDANTS USEFUL AS STABILIZERS AGAINST THERMOOXIDATIVE DEGRADATION OF POLYMERS DURING MELT PROCESSING DOVE CHEMICAL CORPORATION 2004-08-03 US disclosed
US-20030225192-A1 Mxitures of 2-(2-hydroxy-4(3-butoxy-2-hydroxypropyloxy)-phenyl )-4,6-bis(2,4-dimethylphenyl)-1,3,5-triazine and hindered amine light stabilizers, used for stabilization of curable polycarbonates BIRBAUM JEAN-LUC (CH) 2003-12-04 US disclosed
US-20020040081-A1 Blends of phosphites and antioxidants DOVER CHEMICAL 2002-04-04 US disclosed
US-6359148-B1 FOR POLYMER, LUBRICANTS; HEAT, OXIDATION RESISTANCE, PHOTOSTABILITY NESVADBA PETER (CH) 2002-03-19 US disclosed
EP-1087947-A2 TRISARYL-1,3,5-TRIAZINE ULTRAVIOLET LIGHT ABSORBERS CONTAINING HINDERED PHENOLS Ciba SC Holding AG (CH) 2001-04-04 EP disclosed
WO-1999067223-A2 TRISARYL-1,3,5-TRIAZINE ULTRAVIOLET LIGHT ABSORBERS CONTAINING HINDERED PHENOLS CYTEC TECH CORP (US) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225192-A1 Mxitures of 2-(2-hydroxy-4(3-butoxy-2-hydroxypropyloxy)-phenyl )-4,6-bis(2,4-dimethylphenyl)-1,3,5-triazine and hindered amine light stabilizers, used for stabilization of curable polycarbonates SIGMAR1, H1-2, H1-5 NPSR1 520/4885POLB 653/4885NR1H4 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.